Know Cancer

or
forgot password

Observational Retrospective Multicenter Study for the Citofluorimetric Analysis of Cerebrospinal Fluid Vs Conventional Method in Patients With Aggressive Non-Hodgkin's Lymphoma Without Leptomeningeal Disease


N/A
18 Years
N/A
Open (Enrolling)
Both
Diffuse Large Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma

Thank you

Trial Information

Observational Retrospective Multicenter Study for the Citofluorimetric Analysis of Cerebrospinal Fluid Vs Conventional Method in Patients With Aggressive Non-Hodgkin's Lymphoma Without Leptomeningeal Disease


Aggressive B-cell non-Hodgkin's lymphoma (B-NHL), Lymphoblastic Lymphoma and Burkitt's
Lymphoma are at high risk of CNS relapse. For this reason is recommended a prophylaxis
therapy. This suggests that negative leptomeningeal localization patients at diagnosis are
really positive and that would be a very high risk of CNS relapse subtype patients. It's
very important detecting neoplastic cells in cerebrospinal fluid as soon as possible. This
study will evaluate only patients that have been flow cytometry and cytology at diagnosis.


Inclusion Criteria:



1. Diagnosis of

- Diffuse large cell lymphoma HIV positive,

- Lymphoblastic lymphoma,

- Burkitt's lymphoma,

- Mantle cell lymphoma blastoid type.

2. DLCL patients who presented one risk factor for leptomeningeal involvement as:

- testis, bone marrow, orbit, palate, paranasal cavity or peridural disease
localization,

- 2-3 age-adjusted IPI score with more than 1 extranodal site and LDH > normal.

3. Patients with cytologic and flow cytometry on cerebrospinal fluid at diagnosis.

Exclusion Criteria:

1. Patients with clinical or strumental evidence of meningeal localization disease.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Principal Investigator

Umberto Vitolo, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

SCDO Ematologia AOU San Giovanni Battista Torino Italy

Authority:

Italy: Ethics Committee

Study ID:

CFM

NCT ID:

NCT00949741

Start Date:

July 2009

Completion Date:

July 2011

Related Keywords:

  • Diffuse Large Cell Lymphoma
  • Lymphoblastic Lymphoma
  • Burkitt's Lymphoma
  • Burkitt Lymphoma
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

Name

Location